Literature DB >> 3055932

Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncológico Cooperativo del Sur) experience.

B A Leone1, A Romero, M G Rabinovich, C T Vallejo, A Bianco, J E Perez, M Machiavelli, R Rodriguez, L A Alvarez.   

Abstract

The medical records of 414 patients with metastatic breast carcinoma treated between 1978 and 1986 were reviewed and 44 women were identified as having stage IV disease when the primary breast lesion was detected. Of these 44 women, 25 had metastatic disease limited to the skeleton while 19 had extraosseous lesions only. The clinical features, response to therapy, and survival were analyzed and compared for both groups. The median survival of those patients with bone-only metastases was 52 months as compared with 13 months for those with extraskeletal lesions (p = 0.0025). The response rate to first-line systemic therapy was similar for both groups (47% for bone metastases and 44% for extraosseous metastases). The median duration of response was 14 months (range, 3-55 months) for patients with bone disease and 8 months (range, 4-43 months) for those with extraskeletal lesions. We conclude that patients with metastatic breast cancer confined to the skeleton at initial diagnosis tend to follow an indolent, chronic course with prolonged survival. Therefore the increase in response rate with aggressive chemotherapy should be balanced against its higher morbidity. Further studies are needed to confirm whether the better prognosis of these patients is determined by the anatomical confinement of the disease to the skeleton or merely reflects the influence of other prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3055932

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

1.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

2.  Cathepsin D-related disease-free interval in pT1 primary breast carcinomas: a pilot study.

Authors:  D Nikolić-Vukosavljević; M Markićević; G Grujić-Adanja; A Petrović; K Kanjer; Z Nesković-Konstantinović
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study.

Authors:  Montserrat Solá; Mireia Margelí; Eva Castellá; Juan F Julian; Miquel Rull; Josep M Gubern; Antonio Mariscal; Agustí Barnadas; Manuel Fraile
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

4.  Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.

Authors:  Yi-Zi Zheng; Xian-Ming Wang; Lei Fan; Zhi-Ming Shao
Journal:  Oncologist       Date:  2020-11-03       Impact factor: 5.837

5.  Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval.

Authors:  Karynsa Cetin; Christian Fynbo Christiansen; Claus Sværke; Jacob Bonde Jacobsen; Henrik Toft Sørensen
Journal:  BMJ Open       Date:  2015-04-29       Impact factor: 2.692

6.  The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Authors:  Alessio Cortellini; Valentina Cocciolone; Azzurra Irelli; Francesco Pavese; Tina Sidoni; Alessandro Parisi; Paola Lanfiuti Baldi; Olga Venditti; Carla D'Orazio; Pierluigi Bonfili; Pietro Franzese; Luigi Zugaro; Lucilla Verna; Giampiero Porzio; Daniele Santini; Katia Cannita; Corrado Ficorella
Journal:  Oncol Lett       Date:  2018-10-10       Impact factor: 2.967

7.  Cost of managing women presenting with stage IV breast cancer in the United Kingdom.

Authors:  E Remák; L Brazil
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

8.  FER kinase promotes breast cancer metastasis by regulating α6- and β1-integrin-dependent cell adhesion and anoikis resistance.

Authors:  I A Ivanova; J F Vermeulen; C Ercan; J M Houthuijzen; F A Saig; E J Vlug; E van der Wall; P J van Diest; M Vooijs; P W B Derksen
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

9.  Relation between primary tumor FDG avidity and site of first distant metastasis in patients with breast cancer.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Young-Hyuck Im; Yearn Seong Choe; Byung-Tae Kim; Kyung-Han Lee
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

10.  Characterization of bone only metastasis patients with respect to tumor subtypes.

Authors:  Amanda Parkes; Katherine Clifton; Aydah Al-Awadhi; Oluchi Oke; Carla L Warneke; Jennifer K Litton; Gabriel N Hortobagyi
Journal:  NPJ Breast Cancer       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.